nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—PSMB8—pancreas—bile duct cancer	0.0431	0.108	CbGeAlD
Carfilzomib—PSMB10—liver—bile duct cancer	0.0426	0.107	CbGeAlD
Carfilzomib—PSMB5—pancreas—bile duct cancer	0.0381	0.0957	CbGeAlD
Carfilzomib—PSMB1—pancreas—bile duct cancer	0.0333	0.0837	CbGeAlD
Carfilzomib—PSMB10—lymph node—bile duct cancer	0.0327	0.082	CbGeAlD
Carfilzomib—PSMB2—pancreas—bile duct cancer	0.0325	0.0816	CbGeAlD
Carfilzomib—PSMB8—liver—bile duct cancer	0.0274	0.0689	CbGeAlD
Carfilzomib—PSMB5—liver—bile duct cancer	0.0242	0.0609	CbGeAlD
Carfilzomib—PSMB1—liver—bile duct cancer	0.0212	0.0532	CbGeAlD
Carfilzomib—PSMB8—lymph node—bile duct cancer	0.021	0.0529	CbGeAlD
Carfilzomib—PSMB2—liver—bile duct cancer	0.0207	0.0519	CbGeAlD
Carfilzomib—PSMB5—lymph node—bile duct cancer	0.0186	0.0467	CbGeAlD
Carfilzomib—PSMB1—lymph node—bile duct cancer	0.0162	0.0408	CbGeAlD
Carfilzomib—PSMB2—lymph node—bile duct cancer	0.0159	0.0398	CbGeAlD
Carfilzomib—ABCB1—pancreas—bile duct cancer	0.00496	0.0125	CbGeAlD
Carfilzomib—ABCB1—liver—bile duct cancer	0.00316	0.00793	CbGeAlD
Carfilzomib—ABCB1—lymph node—bile duct cancer	0.00242	0.00608	CbGeAlD
Carfilzomib—PSMB10—Disease—SMAD4—bile duct cancer	0.000868	0.00144	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—ERBB2—bile duct cancer	0.000867	0.00144	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—SMAD4—bile duct cancer	0.000864	0.00143	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—ERBB2—bile duct cancer	0.000863	0.00143	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—KRAS—bile duct cancer	0.000788	0.00131	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—FAR2—bile duct cancer	0.000767	0.00127	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—GNAS—bile duct cancer	0.000741	0.00123	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—GNAS—bile duct cancer	0.000737	0.00122	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—SLC5A5—bile duct cancer	0.000722	0.0012	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—SLC5A5—bile duct cancer	0.000722	0.0012	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—SLC5A5—bile duct cancer	0.000722	0.0012	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—SLC5A5—bile duct cancer	0.000712	0.00118	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—SMAD4—bile duct cancer	0.000708	0.00118	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—SMAD4—bile duct cancer	0.000708	0.00118	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—SMAD4—bile duct cancer	0.000708	0.00118	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—TGFB1—bile duct cancer	0.000699	0.00116	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—SMAD4—bile duct cancer	0.000698	0.00116	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFBR2—bile duct cancer	0.000695	0.00115	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFBR2—bile duct cancer	0.000695	0.00115	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFBR2—bile duct cancer	0.000695	0.00115	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HGF—bile duct cancer	0.000691	0.00115	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HGF—bile duct cancer	0.000691	0.00115	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HGF—bile duct cancer	0.000691	0.00115	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFBR2—bile duct cancer	0.000685	0.00114	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HGF—bile duct cancer	0.000682	0.00113	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—HRAS—bile duct cancer	0.00067	0.00111	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—NRAS—bile duct cancer	0.00066	0.0011	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—SMAD4—bile duct cancer	0.000658	0.00109	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—SMAD4—bile duct cancer	0.000658	0.00109	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—SMAD4—bile duct cancer	0.000658	0.00109	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—ERBB2—bile duct cancer	0.000657	0.00109	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—ERBB2—bile duct cancer	0.000657	0.00109	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—ERBB2—bile duct cancer	0.000657	0.00109	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—NRAS—bile duct cancer	0.000657	0.00109	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—SMAD4—bile duct cancer	0.000648	0.00108	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—ERBB2—bile duct cancer	0.000648	0.00108	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—NOS2—bile duct cancer	0.000646	0.00107	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—NOS2—bile duct cancer	0.000643	0.00107	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFBR2—bile duct cancer	0.000642	0.00107	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL6—bile duct cancer	0.000641	0.00107	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFBR2—bile duct cancer	0.000639	0.00106	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—GNAS—bile duct cancer	0.000619	0.00103	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—GNAS—bile duct cancer	0.000616	0.00102	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SMAD4—bile duct cancer	0.000608	0.00101	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SMAD4—bile duct cancer	0.000605	0.001	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—EGFR—bile duct cancer	0.000601	0.000999	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—EGFR—bile duct cancer	0.000598	0.000994	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—KRAS—bile duct cancer	0.000568	0.000944	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—KRAS—bile duct cancer	0.000565	0.000939	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—GNAS—bile duct cancer	0.000561	0.000932	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—GNAS—bile duct cancer	0.000561	0.000932	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—GNAS—bile duct cancer	0.000561	0.000932	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—GNAS—bile duct cancer	0.000553	0.000919	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TP53—bile duct cancer	0.000551	0.000915	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TP53—bile duct cancer	0.000548	0.000911	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—ERBB2—bile duct cancer	0.000526	0.000874	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—ERBB2—bile duct cancer	0.000524	0.00087	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—NRAS—bile duct cancer	0.0005	0.000831	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—NRAS—bile duct cancer	0.0005	0.000831	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—NRAS—bile duct cancer	0.0005	0.000831	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—NRAS—bile duct cancer	0.000493	0.000819	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NOS2—bile duct cancer	0.000489	0.000813	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NOS2—bile duct cancer	0.000489	0.000813	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NOS2—bile duct cancer	0.000489	0.000813	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	0.000488	0.00081	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFBR2—bile duct cancer	0.000486	0.000808	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFBR2—bile duct cancer	0.000486	0.000808	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFBR2—bile duct cancer	0.000486	0.000808	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—ERBB2—bile duct cancer	0.000486	0.000807	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—ERBB2—bile duct cancer	0.000483	0.000803	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—HRAS—bile duct cancer	0.000483	0.000802	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NOS2—bile duct cancer	0.000483	0.000802	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—HRAS—bile duct cancer	0.00048	0.000798	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFBR2—bile duct cancer	0.00048	0.000797	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	0.000477	0.000792	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PTGS2—bile duct cancer	0.000475	0.000789	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PTGS2—bile duct cancer	0.000473	0.000785	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—GNAS—bile duct cancer	0.000469	0.00078	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—GNAS—bile duct cancer	0.000469	0.00078	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—GNAS—bile duct cancer	0.000469	0.00078	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—GNAS—bile duct cancer	0.000463	0.000769	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SMAD4—bile duct cancer	0.000461	0.000765	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SMAD4—bile duct cancer	0.000461	0.000765	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SMAD4—bile duct cancer	0.000461	0.000765	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—EGFR—bile duct cancer	0.000456	0.000757	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—EGFR—bile duct cancer	0.000456	0.000757	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—EGFR—bile duct cancer	0.000456	0.000757	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SMAD4—bile duct cancer	0.000454	0.000754	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	0.000454	0.000754	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—EGFR—bile duct cancer	0.000449	0.000746	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—KRAS—bile duct cancer	0.00043	0.000715	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—KRAS—bile duct cancer	0.00043	0.000715	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—KRAS—bile duct cancer	0.00043	0.000715	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—KRAS—bile duct cancer	0.000424	0.000705	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—bile duct cancer	0.000418	0.000694	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—bile duct cancer	0.000418	0.000694	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—bile duct cancer	0.000418	0.000694	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—bile duct cancer	0.000412	0.000684	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—NRAS—bile duct cancer	0.0004	0.000665	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ERBB2—bile duct cancer	0.000399	0.000662	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ERBB2—bile duct cancer	0.000399	0.000662	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ERBB2—bile duct cancer	0.000399	0.000662	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—NRAS—bile duct cancer	0.000398	0.000662	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PTGS2—bile duct cancer	0.000398	0.000661	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PTGS2—bile duct cancer	0.000396	0.000658	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ERBB2—bile duct cancer	0.000393	0.000653	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—IDH2—bile duct cancer	0.000375	0.000622	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—NRAS—bile duct cancer	0.000369	0.000614	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—ERBB2—bile duct cancer	0.000368	0.000612	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—ERBB2—bile duct cancer	0.000368	0.000612	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—ERBB2—bile duct cancer	0.000368	0.000612	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—NRAS—bile duct cancer	0.000368	0.000611	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HRAS—bile duct cancer	0.000366	0.000608	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HRAS—bile duct cancer	0.000366	0.000608	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HRAS—bile duct cancer	0.000366	0.000608	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—EGFR—bile duct cancer	0.000365	0.000606	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—ERBB2—bile duct cancer	0.000363	0.000603	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—EGFR—bile duct cancer	0.000363	0.000603	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HRAS—bile duct cancer	0.000361	0.000599	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTGS2—bile duct cancer	0.00036	0.000598	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTGS2—bile duct cancer	0.00036	0.000598	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTGS2—bile duct cancer	0.00036	0.000598	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTGS2—bile duct cancer	0.000355	0.00059	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000353	0.000586	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.000345	0.000573	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KRAS—bile duct cancer	0.000344	0.000572	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—TGFB1—bile duct cancer	0.000343	0.00057	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KRAS—bile duct cancer	0.000343	0.00057	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TGFB1—bile duct cancer	0.000342	0.000568	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—ERBB2—bile duct cancer	0.00034	0.000565	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—ERBB2—bile duct cancer	0.000338	0.000562	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000338	0.000562	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EGFR—bile duct cancer	0.000337	0.000559	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EGFR—bile duct cancer	0.000335	0.000557	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—IDH1—bile duct cancer	0.000322	0.000535	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000319	0.000531	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KRAS—bile duct cancer	0.000318	0.000528	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KRAS—bile duct cancer	0.000316	0.000526	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NRAS—bile duct cancer	0.000303	0.000504	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NRAS—bile duct cancer	0.000303	0.000504	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NRAS—bile duct cancer	0.000303	0.000504	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—bile duct cancer	0.000301	0.000501	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—bile duct cancer	0.000301	0.000501	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—bile duct cancer	0.000301	0.000501	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NRAS—bile duct cancer	0.000299	0.000497	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—bile duct cancer	0.000297	0.000494	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—bile duct cancer	0.000293	0.000486	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—bile duct cancer	0.000292	0.000485	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—bile duct cancer	0.000291	0.000484	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—bile duct cancer	0.00029	0.000482	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000284	0.000472	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—bile duct cancer	0.00028	0.000466	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NRAS—bile duct cancer	0.00028	0.000465	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NRAS—bile duct cancer	0.00028	0.000465	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NRAS—bile duct cancer	0.00028	0.000465	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—bile duct cancer	0.000279	0.000463	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—bile duct cancer	0.000276	0.000459	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—bile duct cancer	0.000276	0.000459	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—bile duct cancer	0.000276	0.000459	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NRAS—bile duct cancer	0.000276	0.000459	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—bile duct cancer	0.000272	0.000453	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—bile duct cancer	0.00027	0.000449	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—bile duct cancer	0.000269	0.000447	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—bile duct cancer	0.000261	0.000434	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—bile duct cancer	0.000261	0.000434	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—bile duct cancer	0.000261	0.000434	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—bile duct cancer	0.00026	0.000432	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—bile duct cancer	0.00026	0.000432	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—bile duct cancer	0.00026	0.000432	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—bile duct cancer	0.000259	0.00043	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—bile duct cancer	0.000259	0.00043	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—bile duct cancer	0.000258	0.000428	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—bile duct cancer	0.000258	0.000428	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—bile duct cancer	0.000258	0.000428	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—bile duct cancer	0.000258	0.000428	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—bile duct cancer	0.000257	0.000428	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—bile duct cancer	0.000257	0.000428	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—bile duct cancer	0.000257	0.000426	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—bile duct cancer	0.000255	0.000424	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—bile duct cancer	0.000255	0.000424	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—bile duct cancer	0.000255	0.000424	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—bile duct cancer	0.000254	0.000422	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—bile duct cancer	0.000252	0.000418	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—bile duct cancer	0.000241	0.0004	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—bile duct cancer	0.000241	0.0004	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—bile duct cancer	0.000241	0.0004	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—bile duct cancer	0.00024	0.000399	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—bile duct cancer	0.000239	0.000398	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—bile duct cancer	0.000238	0.000395	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—bile duct cancer	0.000236	0.000392	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—bile duct cancer	0.000235	0.00039	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—bile duct cancer	0.000223	0.00037	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—bile duct cancer	0.000222	0.000369	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—bile duct cancer	0.000222	0.000369	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—bile duct cancer	0.000222	0.000369	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—bile duct cancer	0.000222	0.000368	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—bile duct cancer	0.000221	0.000367	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—bile duct cancer	0.000221	0.000367	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—bile duct cancer	0.000221	0.000367	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—bile duct cancer	0.000219	0.000363	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—bile duct cancer	0.000218	0.000362	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC5A5—bile duct cancer	0.000212	0.000353	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—bile duct cancer	0.000212	0.000353	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—bile duct cancer	0.000212	0.000353	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—bile duct cancer	0.000212	0.000353	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—bile duct cancer	0.000209	0.000348	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—bile duct cancer	0.000205	0.00034	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—bile duct cancer	0.000205	0.00034	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—bile duct cancer	0.000205	0.00034	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—bile duct cancer	0.000202	0.000336	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—bile duct cancer	0.000198	0.000329	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—bile duct cancer	0.000197	0.000327	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—bile duct cancer	0.000196	0.000326	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—bile duct cancer	0.000196	0.000326	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—bile duct cancer	0.000196	0.000326	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—bile duct cancer	0.000196	0.000326	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—bile duct cancer	0.000196	0.000326	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—bile duct cancer	0.000196	0.000326	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—bile duct cancer	0.000193	0.000321	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—bile duct cancer	0.000193	0.000321	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—bile duct cancer	0.000189	0.000315	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—bile duct cancer	0.000188	0.000313	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—bile duct cancer	0.000182	0.000303	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—bile duct cancer	0.000182	0.000303	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—bile duct cancer	0.000182	0.000303	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—bile duct cancer	0.000181	0.000301	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—bile duct cancer	0.00018	0.0003	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—bile duct cancer	0.00018	0.000298	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—bile duct cancer	0.000179	0.000297	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—bile duct cancer	0.000179	0.000297	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—bile duct cancer	0.000179	0.000297	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—bile duct cancer	0.000176	0.000293	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—bile duct cancer	0.000169	0.00028	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—bile duct cancer	0.000169	0.00028	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—bile duct cancer	0.000169	0.00028	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—bile duct cancer	0.000166	0.000276	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNAS—bile duct cancer	0.000165	0.000274	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—bile duct cancer	0.00015	0.000249	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—bile duct cancer	0.00015	0.000249	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—bile duct cancer	0.00015	0.000249	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—bile duct cancer	0.000148	0.000246	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—bile duct cancer	0.000143	0.000238	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—bile duct cancer	0.000143	0.000238	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—bile duct cancer	0.000143	0.000238	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—bile duct cancer	0.000141	0.000235	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—bile duct cancer	0.000137	0.000228	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—bile duct cancer	0.000137	0.000228	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—bile duct cancer	0.000137	0.000228	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—bile duct cancer	0.000135	0.000225	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—bile duct cancer	8.87e-05	0.000147	CbGpPWpGaD
